Results 281 to 290 of about 5,889,184 (390)

Prostate Cancer Detection: A View of the Future

, 2010
Ian M. Thompson, Robin J. Leach, Donna P. Ankerst   +2 more
openalex   +2 more sources

CD168 Identifies Proliferating Pancreatic Islet Cells in Murine and Human

Advanced Science, EarlyView.
This study identifies CD168 as a conserved surface marker for proliferating β‐cells in mouse, human islets, and pancreatic islet tumors. CD168⁺ cells show high proliferation and low insulin expression. CD168+ cells form mostly uni‐β lineage clones, and some of the clones are multi‐lineage.
Shubo Yuan, Jiafu Li, Min Shao, Haili Bao, Ajun Geng, Jialin Yang, Yu Tao, Xinyi Chen, Tianxiong Xiao, Chunye Liu, Zhiyao Xie, Wenqian Song, Qing Cissy Yu, Hongxing Fu, Xu Han, Taochen He, Wenquan Wang, Jianfeng Chen, Sheng Yan, Shaohua Song, Liang Liu, Yi Arial Zeng   +21 more
wiley   +1 more source

GLP1 receptor agonism alters growth and therapeutic response in prostate cancer. [PDF]

Endocr Relat Cancer
Bera S, Gutgesell LC, Darden B, Sargis RM, Maienschein-Cline M, Gaber CE, Reizine NM, Vander Griend DJ, Vellky JE.   +8 more
europepmc   +1 more source

FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma

Advanced Science, EarlyView.
FXYD3 binds IRF7 via its 60–87aa domain, triggering a cGAS/STING‐mediated positive feedback loop amplified by type I interferon. This sustains JAK2/STAT5 activation, accelerating ICC progression. Targeting FXYD3 with siFXYD3@PEP suppresses tumors and enhances chemotherapy sensitivity. Abstract Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis,
Yan Zhou, Xiaofeng Shen, Shuo Zhang, XiaoHong Pu, Zipeng Xu, Xiang Zhao, Wei Feng, Yuan Liang, Xingtao He, Aihua Yang, Yudong Qiu, Yihang Yuan, Chaobo Chen, Jun Chen   +13 more
wiley   +1 more source

Evaluating the impact of a community-based prostate cancer screening program. [PDF]

Arch Public Health
Leader AE, Pham K, Cianci N, Knapp H, Doka F, Barron S, Kolesnikov O, DeHoratius J, Bradley K, Robles L, Giamboy R, Dahlgren O, Gomella LG.   +12 more
europepmc   +1 more source

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

New England Journal of Medicine, 2017
N. James, J. D. de Bono, M. Spears, N. Clarke, M. Mason, D. Dearnaley, A. Ritchie, C. Amos, C. Gilson, Robert J. Jones, D. Matheson, R. Millman, G. Attard, S. Chowdhury, W. Cross, S. Gillessen, C. Parker, M. Russell, D. Berthold, C. Brawley, F. Adab, San Aung, A. Birtle, J. Bowen, S. Brock, P. Chakraborti, C. Ferguson, J. Gale, E. Gray, M. Hingorani, P. Hoskin, J. Lester, Z. Malik, F. McKinna, N. McPhail, J. Money-Kyrle, J. O’Sullivan, O. Parikh, A. Protheroe, A. Robinson, N. Srihari, Carys W Thomas, J. Wagstaff, J. Wylie, A. Zarkar, M. Parmar, M. Sydes   +46 more
semanticscholar   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

Prostate cancer statistics, 2025. [PDF]

CA Cancer J Clin
Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL.   +5 more
europepmc   +1 more source

Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription

Advanced Science, EarlyView.
This study identifies the transcription factor Nuclear Factor I‐B (NFIB) as a key suppressor of liver fibrosis. NFIB expression declines during hepatic stellate cell activation, and its overexpression reduces fibrosis in mice models. The mechanism involves NFIB directly repressing chemokine C─C motif ligand 5 (CCL5), thereby alleviating oxidative ...
Qianqian Chen, Fajuan Rui, Zhiwen Fan, Hongju Yang, Nan Geng, Chenqi Lu, Wenjing Ni, Yue Huan, Junping Shi, Chao Wu, Shengxia Yin, Wei An, Xia Lu, Qianwen Zhao, Jie Li   +14 more
wiley   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source